Breast Cancer: Dolly's Survivor Story

Patient Info: Dolly Chua, Female

As of July 2025, Dolly had completed surgery for breast and thyroid tumors, described feeling wonderful and strong, and remained connected to follow-up care; the source does not explicitly state NED or recurrence status.

City of HopeRead more →

HER2-positive breast cancer with brain, skin, and lymph-node metastases responding to dual-targeted therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: HER2-positive breast cancer. Initial tumor was ER/PR negative with Ki-67 30%; skin metastasis had Ki-67 70%.

Metastatic Site: brain, left cervical lymph nodes, skin of left chest…

After 1 cycle of inetetamab trastuzumab, pyrotinib, and capecitabine, skin metastases regressed, CEA and CA125 decreased, brain lesions shrank, and the largest lesion decreased by about 46%, meeting partial response; disease remained stable as of September 2024.

PubMed CentralRead more →

Stage IV HER2-Positive Breast Cancer: Elissa's Patient Story

Patient Info: Elissa, Female, Under 40 | Stage IV

Biomarkers: HER2-positive; no hereditary mutation reported

Metastatic Site: lymph nodes, liver, spine

Elissa had Stage IV HER2-positive metastatic breast cancer with an early strong response to systemic therapy, but she described the disease as long-term and not curative. As of July 2025, she had lived with metastatic breast cancer for about 4 years and had received roughly 5 lines of treatment.

The Patient StoryRead more →

Isolated adrenal metastasis from breast cancer: adrenalectomy and exemestane plus palbociclib

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; GATA3-positive; CK7-positive; mammaglobin-positive; GCDFP-15 rare staining

Metastatic Site: right adrenal gland

After laparoscopic right adrenalectomy for isolated metastatic breast carcinoma, follow-up CT abdomen/pelvis and PET-CT showed no metastatic disease elsewhere; surveillance while on exemestane and palbociclib showed no recurrence so far.

PubMed CentralRead more →

Stage III Triple-Negative Breast Cancer: Lynn's Survivor Story

Patient Info: Lynn Leiro, Female, Under 40 | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative

Lynn achieved complete response after breast cancer treatment and remission from therapy-related acute lymphocytic leukemia after CAR T cell therapy and bone marrow transplant; as of July 2025, nearly 1 year post-transplant, she was doing better and getting stronger.

City of HopeRead more →

Recovering From a Severe Immune Side Effect During Breast Cancer Treatment

Patient Info: Anonymized, Female, 60s

Recovered from the severe immune-related nerve and muscle complication and proceeded to breast cancer surgery; at 8 months she had returned to normal daily function.

PubMed CentralRead more →

ER/PR-positive breast cancer with separate solitary rib plasmacytoma: disease-free after breast and plasmacytoma treatment

Patient Info: Anonymized, Female, 60s

Biomarkers: Breast cancer: ER-positive, PR-positive, HER2-negative

More than 5 years after treatment, she remained disease-free with no recurrence of either ER/PR-positive breast cancer or the separate solitary rib plasmacytoma.

PubMed CentralRead more →

Stage IIIB triple-negative breast cancer: complete response after LVAD-supported neoadjuvant immunotherapy

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative; Ki-67 95%; nuclear grade 3, triple negative

As of July 2025, breast cancer remained in remission 2.5 years after mastectomy, after neoadjuvant paclitaxel/carboplatin/pembrolizumab, surgery, radiation, and 1 year of adjuvant pembrolizumab.

PubMed CentralRead more →

HER2-Positive Pleomorphic Lobular Breast Cancer in a 43-Year-Old Woman

Patient Info: Anonymized, Female, 40s

Biomarkers: HER2-positive, ER-negative, PR-negative

Postoperative adjuvant treatment continued with HER2-targeted therapy after chemotherapy and radiation.

PubMed CentralRead more →

HER2-low lobular breast cancer with bone marrow involvement responding to T-DXd

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Initial surgical specimen: ER-positive; PR-negative; HER2-negative. Bone marrow relapse: breast cancer infiltration with low HER2 staining.

Metastatic Site: bone marrow

Two years after starting T-DXd, this patient remained free of bone marrow disease and continued the same treatment regimen.

PubMed CentralRead more →

Stage 4 triple-negative breast cancer: NED after adrenalectomy

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative; CA 15-3 elevated at recurrence; normalized post-surgery

Metastatic Site: adrenal gland

After adrenalectomy, serum CA15-3 and metanephrine/normetanephrine levels normalized, and the preoperative workup had found no other metastatic disease.

PubMed CentralRead more →

HER2-low lobular breast cancer with bone marrow involvement treated with T-DXd

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Initial surgical specimen: ER-positive; PR-negative; HER2-negative. Bone marrow relapse: breast cancer infiltration with low HER2 staining.

Metastatic Site: bone marrow

Two years after starting T-DXd, this patient remained free of bone marrow disease and continued the same treatment regimen.

PubMed CentralRead more →

Breast cancer survivorship: radiation-related esophageal stricture and H. heilmannii gastritis treated after therapy

Patient Info: Anonymized, Female, 70+

Biomarkers: Breast tumor biomarkers not reported; initial gastric biopsies H. pylori-negative; repeat gastric biopsies showed H. heilmannii organisms

After completing breast cancer surgery and chemoradiotherapy, post-treatment dysphagia and gastritis resolved with esophageal dilation, proton pump inhibitor therapy, and bismuth-based quadruple therapy for H. heilmannii.

PubMed CentralRead more →

Triple-Negative Breast Cancer: LaToya's Survivor Story

Patient Info: LaToya Bolds-Johnson, Female

Biomarkers: Triple-negative breast cancer

As of June 2025, LaToya was described as a triple-negative breast cancer survivor, Physician Associate, and clinical-trials advocate; the record supports advocacy around trials, not that a trial was her own received treatment.

Stage III HR-Positive Invasive Lobular Carcinoma: Courtney's Patient Story

Patient Info: Courtney, Female, Under 40 | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative

As of June 2025, Courtney was recovering from Stage III ER-positive, PR-positive, HER2-negative ILC treatment after double mastectomy, Taxotere/Cytoxan chemotherapy, and 25 rounds of radiation, with reconstructive surgery delayed by radiation skin injury.

Lobular Breast Cancer AllianceRead more →

Stage 2 secretory breast cancer: surgery alone with clear margins

Patient Info: Anonymized, Female, 40s | Stage II

Biomarkers: ER-positive; PR-negative; HER2-negative; secretory carcinoma; low grade

At 1-month follow-up after modified radical mastectomy, she had no surgical site infection, no arm lymphedema, no scapular winging, full shoulder range of motion, and no evidence of nodal or distant disease.

PubMed CentralRead more →

Malignant Phyllodes Tumor With Breast Rupture and 10 Years Without Recurrence

Patient Info: Anonymized, Female, 50s

No tumor recurrence was seen during 10 years of follow-up after mastectomy and radiation.

PubMed CentralRead more →

Ruptured Malignant Phyllodes Tumor Treated With Emergency Mastectomy

Patient Info: Anonymized, Female, 70+

A 71-year-old woman with a rapidly growing, bleeding malignant phyllodes tumor required emergency mastectomy followed by radiation therapy.

PubMed CentralRead more →

HER2-positive breast cancer with metastatic recurrence and complete response to T-DM1

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: HER2 IHC 3+ and hormone receptor-negative in primary and metastatic breast cancer; no liver metastases seen.

Metastatic Site: major pectoralis muscle, lung, broncho-hilar lymph…

After complete radiologic response on T-DM1, treatment was stopped after 22 months because of porto-sinusoidal vascular disorder. Seven months later, she remained asymptomatic and under surveillance with no signs of recurrent disease.

PubMed CentralRead more →

Melissa Eppard: Stage I triple-negative breast cancer survivorship and intimacy recovery story

Patient Info: Melissa Eppard, Female | Stage I

Biomarkers: Triple-negative breast cancer

As of June 2025, Melissa was described as a Stage I triple-negative breast cancer survivor, cancer thriver, coach, and co-founder focused on intimacy, comfort, confidence, and sexual wellness after cancer.

Prior breast cancer with chemoport-related SVC thrombosis causing chylothorax

Patient Info: Anonymized, Female, 70+

PET-CT ruled out residual malignancy, and the right chylothorax resolved within 48 hours after SVC angioplasty/stenting with no recurrence on 3-month follow-up imaging.

PubMed CentralRead more →

HR-Positive Breast Cancer: Sara's Patient Story

Patient Info: Sara Glenn, Female, Under 40

Biomarkers: TP53 mutation / Li-Fraumeni syndrome; ER-positive; HER2-negative

As of June 2025, Sara had completed bilateral mastectomy and reconstruction for ER-positive, HER2-negative breast cancer and was on planned 10-year tamoxifen plus intensive Li-Fraumeni syndrome surveillance for herself and her daughters.

City of HopeRead more →

BRCA1 Breast Cancer: Kathy's Survivor Story

Patient Info: Kathy Baker, Female

Biomarkers: BRCA1 mutation

As of June 2025, Kathy Baker was a breast and ovarian cancer survivor using her experience with BRCA1 testing to advocate for genetic testing access and cascade testing through My Faulty Gene.

Stage IV Breast Cancer: Queen's Patient Story

Patient Info: Queen, Female, Under 40 | Stage IV

As of June 2025, Queen was living with Stage IV/metastatic breast cancer after multiple surgeries, setbacks, spread, and another tumor, while focusing on faith, self-advocacy, and living each day fully.

The Patient StoryRead more →